Regeneron & Sanofi : FDA Accepts Dupixent SBLA For Priority Review In Bullous Pemphigoid Treatment
- Stock Market Stocks to buy Stocks to sell
admin
- 0
- 1 minute read
(RTTNews) – The U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application or sBLA for Dupixent (dupilumab) to treat adults with bullous pemphigoid, Regeneron Pharmaceuticals Inc. (REGN) and Sanofi (SNYNF, SNY) said in a stat
:max_bytes(150000):strip_icc():format(jpeg)/GettyImages-1194842257-aea6c7d2d75f42c6a081581cd0c01fd1.jpg "Breaking Down the Binomial Model to Value an Option")